The therapeutic strategy in children with Juvenile Idiopathic Arthritis

Issue 9/2022

K. Temelkova

In the last 20 years, significant progress has been made in the therapy of juvenile idiopathic arthritis thanks to several factors – the increased use of intra-articular corticosteroids, the earlier initiation of treatment with Methotrexate, but the introduction of biological drugs plays a major role in the improvement in the prognosis of the disease. With their help, more and more children manage to reach remission or maintain minimal activity of the disease. The main groups of biological medications used in childhood for the various categories of JIA are: TNF-α inhibitors, IL-1 inhibitors, IL-6 inhibitors. A new group of promising medications are JAK inhibitors, which have an advantage for children and in their method of administration – oral. Data on the efficacy and safety of the listed groups of drugs give hope for a better prognosis for patients with chronic arthritis.

Address for correspondence:
К. Temelkova 
Clinic of Rheumatology, Hematology and Cardiology,
SBALDB, MU – Sofia
11, „Akad. Ivan Evstratiev Geshov“ Blvd. 
1612, Sofia, Bulgaria